All you need to do is get a cardboard four-cup drink tray, some floral foam, real or fake flowers, a fun drink, a sweet treat ...

Starbucks reveals summer menu return date and new items - New menu is set to launch in the coming weeks ...

Catch tonight's MLB slate: Diamondbacks vs. Orioles, Royals vs. Tigers, Mets vs. Dodgers, and Angels vs. Yankees, as Donnie ...

Young American EV startup, Slate Auto, has shared its latest video update, and it’s a chilly one. The company’s development prototypes were recently put through extreme winter testing in Northern ...

As fuel costs continue to rise, a budget-friendly electric vehicle might be on your radar. The Slate Truck is now taking reservations for orders — you can hold your spot in line for $50. The simple, ...

When you wake up in the morning with a cup of coffee to get you ready for the day ahead, whether you are queuing in line at a coffee shop or steeping coffee grounds in the comfort of your home, do you ...

The software engineering world is currently wrestling with a fundamental paradox of the AI era: as models become more capable, the "systems problem" of managing them has become the primary bottleneck ...

Slate Auto is becoming an example of what a small startup can do with vast amounts of cash. It’s navigated several trials and tribulations and market shifts that other, less well-funded EV startups ...

Slate has hired former Amazon Marketplace vice president Peter Faricy as its new Chief Executive Officer. With Slate Auto nearing the debut of its all-electric vehicle, the startup has appointed Peter ...

Slate Auto, the electric vehicle startup backed by Jeff Bezos, has replaced its CEO months ahead of the launch of its affordable electric truck. Former Amazon Marketplace vice president Peter Faricy ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. Peter Faricy today assumed the role of Chief Executive Officer of Slate Auto, an American electric vehicle startup.

Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent migraines, an area where others—such as Eli Lilly and Amgen—have previously failed.